Senexin C exhibits potent CDK8/19 inhibitory activity with high selectivity. Senexin C is more metabolically stable and provides a more sustained inhibition of CDK8/19-dependent cellular gene expression when compared with the prototype inhibitor Senexin B. Senexin C inhibits MV4-11 leukemia growth in a systemic in vivo model with good tolerability.
